Prospective studies have increasingly focused on HER2 exon 20 insertions in advanced NSCLC; however, little is known regarding the targeted outcomes of pan-ErbB TKIs for the uncommon HER2 ICD missense alterations in real-world settings. Here, ERBB2 is linked to non-small cell lung carcinoma.